Organovo Holdings Inc Stock Nyse
Equities
US68620A1043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 75K | Sales 2025 * | 444K | Capitalization | 11.73M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 156 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 26.4 x |
P/E ratio 2024 * |
-0.59
x | P/E ratio 2025 * |
-0.73
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.09% |
Managers | Title | Age | Since |
---|---|---|---|
Keith Murphy
CEO | Chief Executive Officer | 52 | 06-12-31 |
Thomas Hess
DFI | Director of Finance/CFO | 60 | 21-09-30 |
Steve Kunszabo
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Adam Stern
BRD | Director/Board Member | 60 | 12-01-31 |
Keith Murphy
CEO | Chief Executive Officer | 52 | 06-12-31 |
David Gobel
BRD | Director/Board Member | 71 | 20-09-14 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |